Kimbell & Associates: Trump Administration Issues MAHA Strategy Report of Recommendations to President Trump
If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2.
Salt Lake City Angels Invests in Freyya
The wearable baby monitor trusted by millions globally expands reach to three continents, including North America, Europe, and now Africa.
Dr. Gordon Ringold to advise on various strategies related to the development of the Company’s novel cancer treatment platform
BD Expands Peripheral Artery Disease Awareness Efforts with ‘Love Your Limbs’ Community Screening Initiative
Renowned leaders in neurology, movement disorders, and commercialization join to shape Celeste® market strategy
Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.
Halia Therapeutics Published in Journey of Drug Targeting
The Company filed a substantial non-provisional PCT patent application seeking worldwide protection for its novel cancer treatment platform
Epic Ventures Gains $200M Fresh Capital
Canyon Labs Opens Expanded Facility